Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals

A. Wanchu, S. Arora, A. Bhatnagar, A. Sud, P. Bambery, S. Singh

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Pentoxiphylline, an inhibitor of tumor necrosis factor-α (TNF-α) has been used in the treatment of human immunodeficiency virus (HIV) infection. The inhibition of TNF-α results in decreased immune activation. Beta2 microglobulin (β2M) has been used as a surrogate marker to study the progression of HIV infection. The objective of this study was to see if use of pentoxiphylline resulted in any decline in β2M levels. Twenty patients with HIV infection who were free of opportunistic infections at the time of inclusion in the study and 18 age and sex matched controls were studied. β2M was measured using an enzyme immunoassay before and four weeks after the start of treatment with pentoxiphylline. Mean levels of β2M before therapy were 1.51 ± 0.77 mg/l (range 0.78 - 3.8 mg/l) and were significantly higher (P < 0.001) than the levels among controls [0.72 ± 0.06 mg/l (range 0.46 - 0.88 mg/l)]. β2M levels in patients declined to 0.85 ± 0.22 mg/l (range 0.72 - 1.0 mg/l) after four weeks of therapy and this was statistically significant (P < 0.001). Use of pentoxiphylline for four weeks results in a significant decline in the levels of β2M suggesting that the level of immune activation is reduced with the therapy.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalIndian Journal of Medical Research
Issue numberMAR.
StatePublished - 2001


  • Beta microglobulin
  • Enzyme immunoassay
  • HIV infection
  • Immune activation
  • Pentoxiphyllinet-tumor necrosis factor-α

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Suppression of beta2 microglobulin by pentoxiphylline therapy in asymptomatic HIV infected individuals'. Together they form a unique fingerprint.

Cite this